Picture of Aptinyx logo

APTX Aptinyx Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m-10.16%
3m-40.76%
6m-46.11%
1yr-86.57%
Volume Change (%)
10d/3m-66.9%
Price vs... (%)
52w High-93.48%
50d MA-19.5%
200d MA-72.45%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-95.65%
Return on Equity-90.04%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Aptinyx EPS forecast chart

Profile Summary

Aptinyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company is targeting and modulating N-methyl-D-aspartate receptors (NMDArs), which are focused on brain and nervous system. It has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. The Company’s lead product candidate, NYX-2925 is in Phase II clinical development for the treatment of chronic pain and enables synaptic plasticity in the brain, a mechanism that is differentiated from any therapy used for the treatment of chronic pain. Its products also include NYX-783, which is in Phase II clinical development for the treatment of post-traumatic stress disorder, and NYX-458 is in Phase II clinical development for the treatment of cognitive impairment associated.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
June 24th, 2015
Public Since
June 21st, 2018
No. of Shareholders
104
No. of Employees
40
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
67,715,718

APTX Share Price Performance

Upcoming Events for APTX

Q4 2022 Aptinyx Inc Earnings Release

Q1 2023 Aptinyx Inc Earnings Release

Aptinyx Inc Annual Shareholders Meeting

Similar to APTX

Picture of Abcam logo

Abcam

us flag iconNASDAQ Global Select Market

Picture of Amgen logo

Amgen

us flag iconNASDAQ Global Select Market

Picture of Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Amryt Pharma logo

Amryt Pharma

us flag iconNASDAQ Global Select Market

Picture of Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email